Stem Cell Treatment in Malaysia
Stem Cell Treatment for Stroke
Research Protocol registered with Stem Cell Registry of the Ministry of Health, Malaysia:
Presented at the 3rd International Association of Neurorestoratology Annual Congress (IANRAC III), Beijing 23-25 April 2010:
Foo-Chiang Lee (Malaysia): Multicentre phase II study assessing the safety and efficacy of intracerebral autologous mesenchymal stem cells in chronic stroke patients
Forthcoming presentation at 8th Asian Congress of Neurological Surgeons, Kuala Lumpur, 20-21 November 2010:
Dr. Chee-Pin CHEE, Foo-Chiang LEE, Dr. Moon-Keen LEE, Sze-Piaw Chin, Zaliha Omar. Autologous bone marrow stem cell transplantation for stroke patients: an initial report.
ABSTRACT OF PAPER presented at IANRAC III Beijing
MULTICENTRE PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRACEREBRAL AUTOLOGOUS MESENCHYMAL STEM CELLS IN CHRONIC STROKE PATIENTS.
Dr. Foo-Chiang LEE 1, Dr. Chee-Pin CHEE 2, Dr. Moon-Keen LEE3, Assoc Prof Sze-Piaw Chin4 and Dr. Zaliha Omar5
Consultant Neurosurgeon1, 2, Neurologist3, KL Advanced Neuroscience Associates, Rehabilitation Physician5, Sunway Medical Center, Clinical Research Advisor4, Cytopeutics Pte Ltd, Malaysia.
Stroke is a leading cause of mortality and morbidity worldwide. In Malaysia it accounts for 10,000 patients and 9% of all hospital deaths per year. Initial treatments are aimed at reducing acute brain damage and cerebral protection. This study is to evaluate new modalities of stroke treatments 6 months after the initial phase and natural recovery. Stem cells therapy has offered a novel neurorestorative option having been proven in in-vitro and some clinical settings. Bone Marrow-derived mesenchymal stem cells (BM-MSC) have anti-inflammatory effect in modulating acute brain injury and promote angiogenesis in ischemic rat brains and neurogenesis in the chronic phase. However efficient delivery to the area of infarct remains a challenge. In this clinical study, body weight based dose of BM-MSC is administered via a minimally invasive stereotactic intracerebral implantation to selected MRI based target sites. Size of infarcted areas on serial MRI Brain, overall symptoms, functions and quality of life will be determined. NIHSS, Bartel Index and Modified Rankin Scale assessment will be done up to 2 years.